PortFolio Companies
Fina Bio Solutions LLC
Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.
Mannin Research
Mannin Research Inc. is a Canadian biotech company focused on developing novel therapeutics for vascular dysfunction. Its programs centered on Angiopoietin–Tie2 biology, with an initial emphasis on ophthalmology (notably glaucoma) and broader vascular indications such as ARDS.
The company advanced early-stage R&D largely supported by Canadian non-dilutive funding programs.
20/20 Optimeyes Technologies
OptimEyes' MNP (Mucoadhesive Nanoparticles) platform delivers small-molecule drugs directly to mucosal surfaces via a mucoadhesive polymer system that enables sustained, localized drug release. This approach improves bioavailability, compliance and safety, and supports topical delivery for multiple indications. The technology is applicable to all mucosal surfaces, across ophthalmology, respiratory, urogenital, women’s health, oncology and CNS pathologies.
FABP Biotech Animal Health
FABP Biotech is a spin-off of the Oswaldo Cruz Foundation (Fiocruz) created to develop anti-helminth vaccines for animal use. The company holds the license to explore Fiocruz’s rights for the development and commercialization of vaccines and veterinary products based on Sm14, a member of the Fatty Acid Binding Proteins family.
Saccharide Therapeutics
Saccharide Therapeutics Pty Ltd (ST) is a Melbourne-based biotechnology company developing first-in-class synthetic polysaccharide-based vaccines, including clinical-ready drug candidates ST101 for potential eradication of malaria and ST208 for amplified protection against tuberculosis (TB). Demonstrated efficacy against several major bacterial pathogens and parasites in animal models is highly translatable for a range of additional human therapeutic and veterinary applications.